23 May 2013
Keywords: Geron Corp, BioTime, Letter of intent, Stem cell program, Shares, Warrants
Article | 18 November 2012
A year after announcing its decision to exit stem cell therapy, the USA’s Geron Corp (Nasdaq: GERN) has ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 November 2012
19 November 2012
© 2013 thepharmaletter.com